AU734444B2 - Peptides for the treatment of systemic lupus erythematosus - Google Patents

Peptides for the treatment of systemic lupus erythematosus Download PDF

Info

Publication number
AU734444B2
AU734444B2 AU63065/98A AU6306598A AU734444B2 AU 734444 B2 AU734444 B2 AU 734444B2 AU 63065/98 A AU63065/98 A AU 63065/98A AU 6306598 A AU6306598 A AU 6306598A AU 734444 B2 AU734444 B2 AU 734444B2
Authority
AU
Australia
Prior art keywords
seq
peptide
pharmaceutical composition
laminin
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU63065/98A
Other languages
English (en)
Other versions
AU6306598A (en
Inventor
Yaakov Naparstek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hadasit Medical Research Services and Development Co
Original Assignee
Hadasit Medical Research Services and Development Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Medical Research Services and Development Co filed Critical Hadasit Medical Research Services and Development Co
Publication of AU6306598A publication Critical patent/AU6306598A/en
Application granted granted Critical
Publication of AU734444B2 publication Critical patent/AU734444B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU63065/98A 1997-03-20 1998-03-20 Peptides for the treatment of systemic lupus erythematosus Ceased AU734444B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL120503 1997-03-20
IL12050397A IL120503A0 (en) 1997-03-20 1997-03-20 Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
PCT/IB1998/000415 WO1998042737A2 (en) 1997-03-20 1998-03-20 Peptides for the treatment of systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
AU6306598A AU6306598A (en) 1998-10-20
AU734444B2 true AU734444B2 (en) 2001-06-14

Family

ID=11069947

Family Applications (1)

Application Number Title Priority Date Filing Date
AU63065/98A Ceased AU734444B2 (en) 1997-03-20 1998-03-20 Peptides for the treatment of systemic lupus erythematosus

Country Status (13)

Country Link
US (1) US6228363B1 (pt)
EP (1) EP0972032B1 (pt)
JP (1) JP4459307B2 (pt)
AT (1) ATE348885T1 (pt)
AU (1) AU734444B2 (pt)
CA (1) CA2283792A1 (pt)
DE (1) DE69836679T2 (pt)
DK (1) DK0972032T3 (pt)
ES (1) ES2279567T3 (pt)
IL (2) IL120503A0 (pt)
NZ (1) NZ337953A (pt)
PT (1) PT972032E (pt)
WO (1) WO1998042737A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6090200A (en) * 1999-07-15 2001-02-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Peptides and their utility in modulation of behavior of cells expressing alpha3beta1 integrins
US7129052B1 (en) 2000-07-12 2006-10-31 The United States Of America As Represented By The Department Of Health And Human Services Peptides and their utility in modulation of behavior of cells expressing α3β1 integrins
WO2001061349A1 (en) * 2000-02-18 2001-08-23 The University Of Tennessee Research Corporation Detection of microbial deposition and immune response at the basement membrane
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
EP1587525A4 (en) * 2003-01-14 2008-09-10 Teva Pharma PARENTERAL FORMULATIONS OF A PEPTIDE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATODES
CA2605321A1 (en) 2005-04-19 2006-10-26 Eli Lilly And Company Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease
US20100285146A1 (en) * 2007-05-24 2010-11-11 Yaakov Naparstek Peptides and methods for the treatment of systemic lupus erythematosus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266328A (en) * 1990-08-27 1993-11-30 Regents Of The University Of Minnesota Laminin a chain polypeptides from the carboxy terminal globular domain
JPH06504271A (ja) 1990-09-14 1994-05-19 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 免疫グロブリンの構造に基づく生物活性なペプチドのデザイン
US6013628A (en) * 1994-02-28 2000-01-11 Regents Of The University Of Minnesota Method for treating conditions of the eye using polypeptides
IL108811A (en) * 1994-03-01 1998-06-15 Hadasit Med Res Service Immunoassay reagents, kits and methods
US5493008A (en) * 1994-08-15 1996-02-20 The University Of Virginia Patent Foundation Two non-contiguous regions contribute to nidogen binding to a single EGF-like motif of the laminin γ1 chain
EP0765660A3 (en) * 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds

Also Published As

Publication number Publication date
EP0972032A2 (en) 2000-01-19
DE69836679T2 (de) 2007-10-04
DK0972032T3 (da) 2007-04-10
PT972032E (pt) 2007-03-30
IL120503A0 (en) 1997-07-13
JP2001524826A (ja) 2001-12-04
ATE348885T1 (de) 2007-01-15
ES2279567T3 (es) 2007-08-16
IL131950A (en) 2006-07-05
AU6306598A (en) 1998-10-20
WO1998042737A2 (en) 1998-10-01
WO1998042737A3 (en) 1998-11-05
JP4459307B2 (ja) 2010-04-28
NZ337953A (en) 2002-03-28
CA2283792A1 (en) 1998-10-01
DE69836679D1 (de) 2007-02-01
EP0972032B1 (en) 2006-12-20
US6228363B1 (en) 2001-05-08

Similar Documents

Publication Publication Date Title
EP1896497B1 (de) Verfahren zur diagnose von rheumatischen erkrankungen
DE69934228T2 (de) Domäne 1 beta2-gpi polypetiden und deren diagnostische und therepeutische verwendungen
AU734444B2 (en) Peptides for the treatment of systemic lupus erythematosus
US7662382B2 (en) Inducible ligand for α1β1 integrin and uses
JPH10512267A (ja) 新規ペプチド
US7208475B2 (en) Peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
WO1995030439A2 (en) Prevention of tumor metastasis
US5512442A (en) Detection of vascular adhesion protein-1 (VAP-1)
NZ222942A (en) Mitochondrial autoantigen of primary biliary cirrhosis and fragments, production by genetic engineering methods, diagnostic test and pharmaceutical use
US20020054872A1 (en) Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
DE69233673T2 (de) Protein S polypeptide und deren Verwendungen
EP0333517A2 (en) Method and agent for inhibiting the binding of human polymorphonuclear leukocytes to endothelium and compositions therefor
JP4065322B2 (ja) 合成ペプチドおよびそれらを含有する医薬組成物
US20030092065A1 (en) Novel peptide and screening method by using the same
MCJ et al. Decrease of heparan sulfate staining in the glomerular basement membrane in murine lupus nephritis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)